Novo Nordisk has earnt yet another dressing down from the PMCPA. The U.K. | Novo Nordisk has earnt yet another dressing down ...

But Lilly isn't alone in the market, and in the coming years, this space could become more crowded. Today, Lilly competes ...

Thousands of plaintiffs have sued Ozempic manufacturers for failing to warn them about the risk of stomach paralysis.

Safety processes and regulations apply to custom-made medicines, which differ from traditional pharmacies. Now, however, ...

A retrospective cohort study of more than 33,000 patients with type 2 diabetes showed that Novo Nordisk’s GLP-1 may lower the risk of opioid overdose by 42% to up to 68%.

Shares of BioAge Labs (BIOA), a biopharmaceutical company focused on obesity drugs, opened 25% above its initial public ...

In 1970, with a degree from the medical school of the University of Copenhagen (UCPH), Professor Jens Juul Holst embarked on ...

With 890 million people affected globally and 42% of American adults classified as obese, the allure of a "miracle" weight ...

Thousands of plaintiffs have sued Ozempic manufacturers for failing to warn them about the risk of stomach paralysis.

With a reduction in borrowing costs and consequent availability of cheaper capital, drugmakers can ramp up their R&D spending ...

Neither company accepts insurance for their GLP-1 products, but the versions they sell are vastly cheaper than those sold by ...

Pharmaceutical corporations Eli Lilly, Novo Nordisk, and Sanofi have been challenged by Doctors Without Borders to take ...